Taiwan Clinical Trial Consortium for Acute Kidney Injury and Renal Diseases (I) = 台灣急性腎損傷及腎病臨床試驗合作聯盟(I)

The incidence rate of acute kidney injury (AKI) in hospitalized patients is increasing, and the number of deaths associated with dialysis-requiring AKI has more than doubled. In hospitalized patients, AKI results in increased in-hospital and post-hospitalization resource utilization. Currently, the incidence rate of dialysis-requiring AKI is higher than that of end-stage renal disease (ESRD), and its annual growth rate is as high as 10% in the United States. To promote Taiwan Consortium of Acute Kidney Injury and Renal Diseases (CAKs) as the leading kidney diseases of clinical trial group in Asia-Pacific by establishing a cohesive group of kidney clinical trial sites that conduct uniform standard-of-care and high quality clinical trial performance in renal diseases and provide credible and reliable data. The participating investigators of CAKs are specialists of kidney medicine who have experience in conducting bench and clinical studies of AKI. The key missions of the CAKs will be to assist the design and conduct of multi-center investigator-initiated, industry or international research groups) clinical trials, as well as the establishment of biospecimen database of AKI patients. Central office will provide the window of communication, database auditing and the improving quality of specimens, and core study coordination. The core facility of CAKs will provide Standardized analysis for novel AKI biomarkers. Participating subjects need to sign the informed consent for clinical data , PBMC/plasma/serum/ specimens from kidney biopsy. This year , we will work on 1. Improved AKI using “adsorbent，，Clinical prospective multicenter randomized controlled trial (RCT) study.2. The Effect of Endotoxin Adsorbed Hemoperfusion on the Microcirculation in Patients with Severe Sepsis and Septic Shock. 3. Validation the device from Advanced Circuits Research Laboratory By estimation, the consortium has the ability to enroll AKI patients and record the acute dialysis during intensive units. Core clinical information will be collected using a web based information system for future analysis. The ultimate goal for CAKs is to enable clinical trials of potential therapies for AKI and speed the development of treatments that will improve the severity of end stage renal disease and mortality for patients with AKI.